CDK9 and prostate carcinoma: Strikingly, the combined inhibition of CDK7 and CDK9 led to an over 80% decrease in proliferation in the prostate cancer and CRPC cells but did not affect the cell lines derived from normal prostate epithelia (Fig. 4B).